NCT03394677View on ClinicalTrials.gov

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions
Atopic Dermatitis
Interventions
DRUG

RVT-501 0.5% ointment

Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.

DRUG

Vehicle ointment

Placebo comparator - ointment twice daily (BID) for 4 weeks.

Trial Locations (7)

73118

Dermavant Investigational Site, Oklahoma City

75230

Dermavant Investigational Site, Dallas

78213

Dermavant Investigational Site, San Antonio

90045

Dermavant Investigational Site, Los Angeles

97223

Dermavant Investigational Site, Portland

V3R 6A7

Dermavant Investigational Site, Surrey

H2K 4L5

Dermavant Investigational Site, Montreal

Sponsors
All Listed Sponsors
lead

Dermavant Sciences GmbH

INDUSTRY

NCT03394677 - Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter